Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 10
2004 4
2005 10
2006 8
2007 6
2008 5
2009 7
2010 2
2011 3
2012 4
2013 3
2014 1
2015 3
2016 3
2017 2
2018 2
2019 2
2020 3
2021 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Results by year

Filters applied: . Clear all
Page 1
Antiangiogenic metronomic chemotherapy.
Sarmiento R, Gasparini G. Sarmiento R, et al. Among authors: gasparini g. Onkologie. 2008 Apr;31(4):161-2. doi: 10.1159/000119925. Epub 2008 Mar 20. Onkologie. 2008. PMID: 18418015 Free article. No abstract available.
Utility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohort.
Verzeroli C, Giaccherini C, Russo L, Bolognini S, Gamba S, Tartari CJ, Schieppati F, Ticozzi C, Vignoli A, Masci G, Sarmiento R, Spinelli D, Malighetti P, Tondini C, Petrelli F, Giuliani F, D'Alessio A, Gasparini G, Minelli M, De Braud F, Santoro A, Labianca R, Marchetti M, Falanga A; HYPERCAN Investigators. Verzeroli C, et al. Among authors: gasparini g. J Thromb Haemost. 2023 Jul;21(7):1869-1881. doi: 10.1016/j.jtha.2023.03.037. Epub 2023 Apr 11. J Thromb Haemost. 2023. PMID: 37054917 Free article.
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue.
Longo V, Brunetti O, Gnoni A, Cascinu S, Gasparini G, Lorusso V, Ribatti D, Silvestris N. Longo V, et al. Among authors: gasparini g. Oncotarget. 2016 Sep 6;7(36):58649-58658. doi: 10.18632/oncotarget.10765. Oncotarget. 2016. PMID: 27462915 Free PMC article. Review.
A New Risk Prediction Model for Venous Thromboembolism and Death in Ambulatory Lung Cancer Patients.
Gomez-Rosas P, Giaccherini C, Russo L, Verzeroli C, Gamba S, Tartari CJ, Bolognini S, Ticozzi C, Schieppati F, Barcella L, Sarmiento R, Masci G, Tondini C, Petrelli F, Giuliani F, D'Alessio A, Minelli M, De Braud F, Santoro A, Labianca R, Gasparini G, Marchetti M, Falanga A, On Behalf Of The Hypercan Investigators. Gomez-Rosas P, et al. Among authors: gasparini g. Cancers (Basel). 2023 Sep 15;15(18):4588. doi: 10.3390/cancers15184588. Cancers (Basel). 2023. PMID: 37760562 Free PMC article.
Thalidomide: a new anticancer drug?
Fanelli M, Sarmiento R, Gattuso D, Carillio G, Capaccetti B, Vacca A, Roccaro AM, Gasparini G. Fanelli M, et al. Among authors: gasparini g. Expert Opin Investig Drugs. 2003 Jul;12(7):1211-25. doi: 10.1517/13543784.12.7.1211. Expert Opin Investig Drugs. 2003. PMID: 12831355 Review.
Anti-VEGF therapy: the search for clinical biomarkers.
Longo R, Gasparini G. Longo R, et al. Among authors: gasparini g. Expert Rev Mol Diagn. 2008 May;8(3):301-14. doi: 10.1586/14737159.8.3.301. Expert Rev Mol Diagn. 2008. PMID: 18598109 Review.
The paradigm of personalized therapy in oncology.
Gasparini G, Longo R. Gasparini G, et al. Expert Opin Ther Targets. 2012 Mar;16 Suppl 1:S7-16. doi: 10.1517/14728222.2011.637921. Epub 2011 Nov 11. Expert Opin Ther Targets. 2012. PMID: 22073968 Review.
Anti-angiogenic and anti-HER therapy.
Gasparini G, Sarmiento R, Longo R. Gasparini G, et al. Biomed Pharmacother. 2006 Jul;60(6):263-5. doi: 10.1016/j.biopha.2006.06.001. Epub 2006 Jun 23. Biomed Pharmacother. 2006. PMID: 16815667 Review.
77 results